24 July 2025: Owkin teams up with NeoGenomics and France Tissue Bank to build IHC-dedicated foundation model for AI-driven ADC diagnostics
Owkin is developing an AI foundation model trained exclusively on immunohistochemistry (IHC) images to improve diagnostic accuracy and patient selection for antibody-drug conjugate (ADC) therapies
The model addresses key limitations in IHC, including interobserver variability, limited scoring resolution, and difficulty in assessing tumor heterogeneity—challenges that directly impact ADC program efficacy
The collaboration combines AI expertise and high-quality data, leveraging Owkin’s AI technology with NeoGenomics’ real-world pathology datasets and France Tissue Bank’s annotated histological samples
The project aims to accelerate ADC research by providing a public, IHC-specific foundation model that enhances biomarker discovery, supports translational research, and strengthens AI-driven diagnostics in oncology